Broad Institute of MIT and Harvard updated the patent process regarding the CRISPR editing of eukaryotic genomes on Sep 10 2018.
A federal panel CAFC of the United State has again confirmed that the patents granted by USPTO to the Broad Institute, MIT and Harvard concerning CRISPR editing of eukaryotic genomes do not interfere with patent claims filed by the University of California, Berkeley and the University of Vienna.
This means that the Broad Institute will continue to have intellectual property rights in the use of CRISPR gene editing in eukaryotes – the most profitable part of the technology.
UPDATE ON PATENT PROCESS IN THE UNITED STATES BY BROAD INSTITUTE
UNIVERSITY OF CALIFORNIA V. BROAD INSTITUTE, INC. [OPINION] BY CAFC